Champions Oncology (CSBR) Reaches New 52-Week High After Strong Earnings
Champions Oncology Inc (NASDAQ:CSBR) reached a new 52-week high during mid-day trading on Friday after the company announced better than expected quarterly earnings. The stock traded as high as $11.00 and last traded at $9.84, with a volume of 34973 shares traded. The stock had previously closed at $10.63.
The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. Champions Oncology had a negative return on equity of 531.69% and a negative net margin of 7.44%. The firm had revenue of $6.23 million for the quarter, compared to analyst estimates of $5.85 million.
Several brokerages recently issued reports on CSBR. Janney Montgomery Scott began coverage on Champions Oncology in a research note on Monday, July 9th. They set a “buy” rating on the stock. Craig Hallum began coverage on Champions Oncology in a research note on Tuesday, July 17th. They set a “buy” rating and a $12.00 price target on the stock. Finally, ValuEngine upgraded Champions Oncology from a “hold” rating to a “buy” rating in a research note on Tuesday, June 5th.
The company has a market cap of $91.64 million, a price-to-earnings ratio of -75.57 and a beta of 0.12.
About Champions Oncology (NASDAQ:CSBR)
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Featured Story: Understanding Average Daily Trade Volume
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.